FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?
You may also be interested in...
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
Advicor, Simcor Withdrawals Show There's A Lot Riding On CV Outcomes Studies
Surrogate markers for cardiovascular products may be going the way of AbbVie's cholesterol franchise.